Background
==========

Hepatocellular carcinoma (HCC), a leading cause of cancer-related deaths worldwide, represents more than 90% of all liver cancer cases \[[@b1-medscimonit-25-1105]\]. Despite advances in HCC treatment, it remains one of the deadliest cancers.

With the development of a series of treatments, such as novel surgical techniques, ablation treatment, transcatheter arterial chemoembolization (TACE), and liver transplantation, HCC patients' survival have been improved in recent years \[[@b2-medscimonit-25-1105]--[@b4-medscimonit-25-1105]\]. It is widely accepted that HCC treatment should be multidisciplinary. Personalized treatment options should be based on various factors, including tumor stage, liver function, and patient's general health condition \[[@b5-medscimonit-25-1105].[@b6-medscimonit-25-1105]\]. Since HCC treatment plans vary widely, different guidelines are proposed by National Comprehensive Cancer Network (NCCN), European Association for the Study of the Liver-European Organization for Research and Treatment of Cancer (EASLEORTC), and the Asian Oncology Summit 2009 (AOS). To preserve liver function and improve long-term survival, surgical resection is thought to be the only curative treatment \[[@b7-medscimonit-25-1105]\]. Patients undergoing surgery are evaluated by clinical and biochemical measures, including hepatic volumetry, surgically feasibility at tumor location, adequate liver reserve, and sufficient liver remnant \[[@b8-medscimonit-25-1105].[@b9-medscimonit-25-1105]\].

HCC is often diagnosed when it becomes an advanced disease. HCC frequently metastasizes to bone, including the spine, pelvis, and ribs \[[@b10-medscimonit-25-1105]\]. Bone metastases (BM) occur in 2--25% of metastatic HCC, and BM frequently leads to poor HCC prognosis \[[@b1-medscimonit-25-1105],[@b11-medscimonit-25-1105],[@b12-medscimonit-25-1105]\]. Among all patients with BM, 40% are spinal, which leads to skeletal-related events (SREs), including pathological fractures, need for surgery or radiotherapy, spinal cord compression, and malignant hypercalcemia \[[@b13-medscimonit-25-1105]\]. Previously, none of the guidelines suggested performing routine assessment for BM screening in HCC patients. With the development of medical and nursing technology, the survival of HCC has been prolonged, resulting in increased risk of BM development \[[@b14-medscimonit-25-1105]--[@b17-medscimonit-25-1105]\]. Thus, to promote early diagnosis of BM in HCC and to further improve the survival of HCC patients with BM, the characteristics of HCC patients with BM should be summarized.

In the present study, using the Surveillance, Epidemiology, and End Results (SEER) database, we evaluated the prevalence and the risk factors of bone metastases in hepatocellular carcinoma. Furthermore, we performed survival analyses and identified prognostic factors among the HCC patients with BM.

Material and Methods
====================

Study population
----------------

Data were obtained from the Surveillance, Epidemiology, and End Results (SEER) database using SEER\*Stat 8.3.5 software. Since the details of metastases were not recorded before 2010, primary HCC patients who were aged ≥18 years at diagnosis between 2010 and 2015 were collected. The primary site was labeled as "Liver and Intrahepatic Bile Duct", and histological types for HCC were limited to 8170/3, 8171/3, 8172/3, 8173/3, 8174/3, and 8175/3 according to the International Classification of Diseases for Oncology-3 (ICD-O-3). The exclusion criteria were as follows: diagnosed with carcinoma *in situ* and benign, diagnosed at autopsy or via death certificate, unknown bone metastases, or follow-up.

A total of 36 507 patients identified as having HCC from 1 January 2010 to 31 December 2015 were enrolled to analyze BM prevalence and risk factors. Among those, 1263 initially diagnosed HCC patients with BM between 2010 and 2014 were retrieved for conducting survival analysis. Furthermore, to compare the characteristics between different treatment groups (with or without surgery of primary site), 3 of 1263 patients were excluded because surgical status was not provided.

Statistical analysis
--------------------

Patient demographic and clinical characteristics were: age (≤40, 41--60, 61--80, and ≥81 years); sex (female and male); race \[white, black, AI (American Indian/Alaska Native), and API (Asian or Pacific Islander)\]; marital status (married and unmarried); insurance status (insured and uninsured); primary tumor (T) stage (T1, T2, T3, and T4); regional lymph node stage (N0 and N1); tumor differentiation grade (grade I, grade II, grade III, and grade IV), presence or absence of lung metastases, intrahepatic metastases, or brain metastases; AFP (alpha fetoprotein, normal and elevated); and fibrosis score (0 and 1). The risk factors for HCC patients with initial BM were determined primarily by univariate logistic regression. If the characteristic was significant (with *P*\<0.05) by univariate logistic regression, then the risk factors were further analyzed using a multivariate logistic regression model. The primary outcome of the survival analysis was the overall survival, which was defined as from the time of diagnosis of HCC to all causes of death. Kaplan-Meier curves and log-rank tests were employed to analyze survival differences. We also performed multivariable Cox proportional hazards regression based on the aforementioned factors with p-value \<0.05 and the surgical treatments of primary site (None or Yes). Furthermore, the difference in the demographic and clinical characteristics between HCC patients receiving surgical treatments and the ones without surgery were determined by univariate and multivariate logistic regression. All statistical analyses were performed using SPSS 23.0 (IBM Corporation, Armonk, NY) and all charts on survival were prepared by MedCalc 15.2.2. Two-sided *p*\<0.05 was considered as statistically significant.

Results
=======

Prevalence of bone metastases
-----------------------------

Based on the inclusion criteria, a total of 36 507 eligible patients were collected. The prevalence of BM was 4.29% (1567/36 507) in the entire cohort with the initial diagnosis ([Table 1](#t1-medscimonit-25-1105){ref-type="table"}). Among those, 1263 HCC patients with initial BM were followed up to more than 1 year ([Table 2](#t2-medscimonit-25-1105){ref-type="table"}).

Risk factors for developing bone metastasis
-------------------------------------------

Univariate analysis showed multiple factors were significantly associated with BM occurrence. These factors were: male sex (OR=1.80, 95% CI: 1.56--2.08, *P*\<0.001); race (OR=0.92, 95% CI: 0.88--0.97, *P*=0.001); marital status (OR=1.13, 95% CI: 1.02--1.25, *P*=0.02); insurance status (OR=1.45, 95% CI: 1.16--1.81, *P*=0.001); primary tumor (T) stage (OR=1.70, 95% CI: 1.60--1.80, *P*\<0.001); regional lymph node (N) stage (OR=3.92, 95% CI: 3.41--4.50, *P*\<0.001); tumor differentiated grade (OR=1.44, 95% CI: 1.27--1.64, *P*\<0.001); presence of lung metastases (OR=6.01, 95% CI: 5.28--6.83, *P*\<0.001), intrahepatic metastases (OR=9.44, 95% CI: 7.56--11.78, *P*\<0.001), and brain metastases (OR=15.60, 95% CI: 10.68--22.79, *P*\<0.001); and AFP (OR=1.96, 95% CI: 1.67--2.30, *P*\<0.001).

Multivariate logistic regression analyses indicated male sex, unmarried status, higher T stage, higher N stage, and presence of lung metastases, intrahepatic metastases, and brain metastases were positively associated with BM at initial diagnosis ([Table 1](#t1-medscimonit-25-1105){ref-type="table"}).

Survival time and prognostic factors for BM
-------------------------------------------

At the end of follow-up, 95.72% (N=1209) of HCC patients with initial BM had died. The median overall survival for these HCC patients was 3.00 months (95% CI: 2.77--3.24 months, [Figure 1A](#f1-medscimonit-25-1105){ref-type="fig"}), while the median survival of the cohort was 12.00 months (95% CI: 11.66--12.34). The overall survivals of patients with unmarried (*P*\<0.001, [Figure 1B](#f1-medscimonit-25-1105){ref-type="fig"}), uninsured (*P*=0.02), higher primary tumor (T) stage (*P*=0.03), higher regional lymph node (N1) (*P*\<0.001), lung metastases (*P*\<0.001), poor tumor differentiated grade (*P*\<0.001), and elevated AFP (*P*=0.001) were worse than their counterparts. The overall survival of patients with a history of surgical treatment at the primary site was significantly better than in those without surgery (*P*\<0.001, [Figure 1C](#f1-medscimonit-25-1105){ref-type="fig"}). The median survival of patients with surgery at primary site was 9.00 months compared to 3.00 months without surgery ([Table 2](#t2-medscimonit-25-1105){ref-type="table"}).

Both unmarried status (*P*=0.01) and surgical treatment of primary site (*P*=0.001) were significantly associated with overall survival by multivariate Cox regression analyses ([Table 2](#t2-medscimonit-25-1105){ref-type="table"}).

Discussion
==========

To the best of our knowledge, this is the largest population-based study to investigate the prevalence, risk, and prognostic factors for BM in HCC. With the deleterious effect on survival and quality of life caused by BM among HCC patients, a screening approach to determine whether HCC patients have BM should be delineated. The results presented in our study suggest HCC patients have significantly greater odds of BM at diagnosis if they are male, unmarried, have higher T stage, and have lymph node involvement, intrahepatic metastases, and extrahepatic metastases (lung or brain). Accordingly, we propose that skeletal radiographic scanning be considered at diagnosis for HCC patients with the aforementioned factors. The latest relevant study suggested patients with metastatic disease at other locations instead of bone have lower risk of developing BM later; thus, radiographic screening for those patients is not necessary \[[@b1-medscimonit-25-1105]\]. Undoubtedly, more research is needed to verify this proposition.

Various prognostic factors were reported in previous studies, including SREs \[[@b1-medscimonit-25-1105]\], alpha fetoprotein \[[@b18-medscimonit-25-1105]\], Tomita score \[[@b10-medscimonit-25-1105]\], and body mass index \[[@b19-medscimonit-25-1105]\]. In the present study, based on the SEER database, we found 2 prognostic factors of BM among HCC patients at initial diagnosis. The HCC patients were associated with significantly higher risk of mortality if they were unmarried or did not have a history of surgical treatment of the primary liver lesion.

The association of marital status with mortality may be due to various reasons. First, compared with unmarried patients, married patients may have more financial support, which can prompt early diagnosis and timely medical intervention \[[@b20-medscimonit-25-1105],[@b21-medscimonit-25-1105]\]. Second, depression and stress were reported to be associated with tumor metastasis \[[@b22-medscimonit-25-1105],[@b23-medscimonit-25-1105]\]. Compared with unmarried patients, married patients were likely to be less depressed and stressed after being informed of their cancer diagnoses. Undoubtedly, the mechanism underlying this phenomenon needs to be explored.

Extrahepatic metastasis of HCC was long thought to be a terminal event, so neither surgical resection nor ablation were considered \[[@b14-medscimonit-25-1105],[@b15-medscimonit-25-1105]\]. The latest case report indicated that primary liver tumor surgery can improve the survival of HCC patients with BM \[[@b16-medscimonit-25-1105]\]. Although some recent studies reported a series of molecular markers for predicting prognosis of HCC \[[@b24-medscimonit-25-1105]--[@b26-medscimonit-25-1105]\], few studies have reported on surgical treatment of the primary liver tumor among HCC patients with BM. In our study, significantly improved survival was observed among the BM patients who underwent primary liver tumor surgery. However, we attribute this result to biased selection of the patients. In future, randomized comparison clinical trial is warranted.

There are some limitations to the present study. Detailed surgical information is not described in the SEER database. Thus, the surgical indication for the HCC patients who underwent surgery could not be further analyzed. In addition, the number of HCC patients with BM who underwent primary liver tumor surgery was far lower than those without surgery. Moreover, among HCC patients with BM, the asymptomatic cases were not recorded by the SEER database, and the patients who developed BM later in their disease course were not recorded. Thus, the real prevalence of BM might be underestimated. Skeletal-related events, Karnofsky performance status, the etiology (hepatitis B, C, or alcohol), or Child-Pugh classification, which were reported to be the important prognostic factors, are not available in the SEER database, so we could not further confirm these results in the present study.

Conclusions
===========

This study demonstrates that the prevalence of initial BM was 4.29%. Risk of bone metastasis was significantly associated with the following risk factors: male sex, unmarried status, higher T stage, higher N stage, and the presence of lung metastases, intrahepatic metastases, and brain metastases. Unmarried HCC patients with BM tended to have a worse prognosis.
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![Kaplan-Meier analysis of overall survival among patients diagnosed with hepatocellular carcinoma with initial bone metastases (**A**, overall), stratified by marital status (**B**) and surgical treatments of primary site (**C**).](medscimonit-25-1105-g001){#f1-medscimonit-25-1105}

###### 

Multivariable logistic regression analysis of characteristics of hepatocellular carcinoma patients diagnosed with bone metastases.

  Subject characteristics   No. of patients with HCC (2010--2015)   OR (95% CI)   P                      
  ------------------------- --------------------------------------- ------------- ---------------------- ---------
  Sex                                                                                                    
   Female                   228 (2.71)                              8198          1 (Reference)          1.00
   Male                     1339 (4.77)                             26742         1.77 (1.17--2.69)      0.01
  Race                                                                                                   
   White                    1091 (4.32)                             24186         1 (Reference)          1.00
   Black                    278 (5.48)                              4794          1.37 (0.93--2.00)      0.11
   AI                       25 (5.21)                               455           1.73 (0.54--5.61)      0.36
   API                      168 (3.07)                              5312          0.83 (0.52--1.31)      0.42
   Unknown                  5 (2.53)                                193           NA                     NA
  Marital Status                                                                                         
   Married                  721 (4.05)                              17083         1 (Reference)          1.00
   Unmarried                760 (4.55)                              15936         1.61 (1.20--2.20)      0.002
   Unknown                  86 (4.29)                               1921          NA                     NA
  Insurance status                                                                                       
   Insured                  1454 (4.24)                             32863         1 (Reference)          1.00
   Uninsured                88 (6.03)                               1372          1.37 (0.73--2.59)      0.33
   Unknown                  25 (3.42)                               705           NA                     NA
  T stage                                                                         1.20 (1.02--1.41)      0.03
   T1                       332 (2.13)                              15286         1 (Reference)          1.00
   T2                       186 (2.41)                              7521          1.12 (0.73--1.73)      0.61
   T3                       525 (6.16)                              7999          1.66 (1.14--2.41)      0.01
   T4                       96 (7.50)                               1184          1.20 (0.61--2.35)      0.60
   Unknown                  428 (12.67)                             2950          NA                     NA
  Lymph node met.                                                                                        
   N0                       988 (3.15)                              30412         1 (Reference)          1.00
   N1                       288 (11.29)                             2264          2.74 (1.87--4.04)      \<0.001
   Unknown                  291 (11.39)                             2264          NA                     NA
  Grade                                                                           1.04 (0.85--1.27)      0.73
   I                        101 (2.62)                              3747          1 (Reference)          1.00
   II                       149 (2.53)                              5749          0.70 (0.48--1.03)      0.07
   III                      144 (5.43)                              2509          1.15 (0.77--1.73)      0.49
   IV                       9 (4.23)                                204           0.46 (0.10--2.08)      0.31
   Unknown                  1164 (4.87)                             22731         NA                     NA
  Lung met.                                                                                              
   None                     1143 (3.34)                             33063         1 (Reference)          1.00
   Yes                      356 (17.19)                             1715          4.45 (2.93--6.74)      \<0.001
   Unknown                  68 (29.57)                              162           NA                     NA
  Intrahepatic met.                                                                                      
   None                     1386 (3.86)                             34531         1 (Reference)          1.00
   Yes                      114 (27.47)                             301           5.39 (2.77--10.48)     \<0.001
   Unknown                  67 (38.29)                              108           NA                     NA
  Brain met.                                                                                             
   None                     1456 (4.01)                             34828         1 (Reference)          1.00
   Yes                      45 (39.47)                              69            60.90 (25.00--48.33)   \<0.001
   Unknown                  66 (60.55)                              43            NA                     NA
  AFP                                                                                                    
   Normal                   185 (2.38)                              7580          1 (Reference)          1.00
   Elevated                 974 (4.57)                              20349         1.24 (0.86--1.78)      0.25
   Unknown                  408 (5.50)                              7011          NA                     NA

HCC -- hepatocellular carcinoma; AI -- American Indian/Alaska Native; API -- Asian or Pacific Islander; Met -- metastases; NA -- not available; AFP -- alpha fetoprotein. All factors with unknown data were removed from the multivariable logistic regression model.

###### 

Multivariable Cox regression analysis of mortality among hepatocellular carcinoma patients with bone metastases.

  Subject characteristics   No. of HCC patients with BM   Survival, median (95%CI), mo.   HR (95% CI)       P                   
  ------------------------- ----------------------------- ------------------------------- ----------------- ------------------- -------
  Marital status                                                                                                                
   Married                  572                           542 (94.76)                     3 (2.51--3.49)    1 (Reference)       1.00
   Unmarried                619                           597 (96.45)                     2 (1.68--2.32)    1.56 (1.12--2.18)   0.01
   Unknown                  72                            70 (97.22)                      NA                NA                  NA
  Insurance status                                                                                                              
   Insured                  1167                          1118 (95.80)                    3 (2.76--3.24)    1 (Reference)       1.00
   Uninsured                75                            70 (93.33)                      2 (1.36--2.64)    1.15 (0.63--2.10)   0.65
   Unknown                  21                            21 (100.00)                     NA                NA                  NA
  T Stage                                                                                                                       
   T1                       264                           253 (95.83)                     3 (2.31--3.69)    1 (Reference)       1.00
   T2                       147                           139 (94.56)                     3 (2.28--3.72)    1.40 (0.83--2.38)   0.21
   T3                       423                           405 (95.74)                     3 (2.60--3.40)    1.05 (0.70--1.57)   0.82
   T4                       73                            72 (98.63)                      2 (1.31--2.69)    1.40 (0.65--3.02)   0.39
   Unknown                  356                           340 (95.51)                     NA                NA                  NA
  Lymph node met.                                                                                                               
   N0                       780                           742 (95.13)                     3 (2.61--3.39)    1 (Reference)       1.00
   N1                       238                           233 (97.90)                     2 (1.66--2.34)    1.09 (0.72--1.64)   0.69
   Unknown                  245                           234 (95.51)                     NA                NA                  NA
  Grade                                                                                                                         
   I                        82                            73 (89.02)                      5 (3.45--6.55)    1 (Reference)       1.00
   II                       123                           115 (93.50)                     5 (3.75--6.25)    1.05 (0.67--1.65)   0.83
   III                      119                           115 (96.64)                     2 (1.55--2.45)    1.59 (1.01--2.50)   0.047
   IV                       7                             7 (100.00)                      2 (0.00--4.57)    1.29 (0.30--5.60)   0.73
   Unknown                  932                           899 (96.46)                     NA                NA                  NA
  Lung met.                                                                                                                     
   None                     908                           862 (94.93)                     3 (2.60--3.40)    1 (Reference)       1.00
   Yes                      294                           290 (98.64)                     2 (1.69--2.31)    1.41 (0.95--2.10)   0.09
   Unknown                  61                            57 (93.44)                      NA                NA                  NA
  AFP                                                                                                                           
   Normal                   146                           134 (91.78)                     4 (2.73--5.27)    1 (Reference)       1.00
   Elevated                 783                           754 (96.30)                     3 (2.72--3.28)    1.12 (0.76--1.65)   0.57
   Unknown                  334                           321 (96.11)                     NA                NA                  NA
  Surg (pri)                                                                                                                    
   None                     1224                          1176 (96.08)                    3 (2.77--3.23)    1 (Reference)       1.00
   Yes                      36                            30 (83.33)                      9 (6.07--11.94)   0.29 (0.14--0.60)   0.001
   Unknown                  3                             3 (100.00)                      NA                NA                  NA

HCC -- hepatocellular carcinoma; BM -- bone metastases; Met -- metastases; Surg (pri) -- surgical treatments of primary site; NA -- not available; AFP -- alpha fetoprotein. All factors with unknown data removed from the Cox and Kaplan-Meier model.

[^1]: Study Design

[^2]: Data Collection

[^3]: Statistical Analysis

[^4]: Data Interpretation

[^5]: Manuscript Preparation

[^6]: Literature Search

[^7]: Funds Collection

[^8]: Xu Guo, Yao Xu and Xin Wang contributed equally to this work
